NATAZIA DIN 02379112
Health Canada record
| Active ingredient(s) | ESTRADIOL VALERATE 3 MG; ESTRADIOL VALERATE 2 MG; DIENOGEST 2 MG; ESTRADIOL VALERATE 2 MG; DIENOGEST 3 MG; ESTRADIOL VALERATE 1 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03AB08 DIENOGEST AND ESTROGEN |
| Original market date | |
| Current status date | 10-Jul-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESTRADIOL VALERATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00029238 | DELESTROGEN INJ 10MG/ML | THERAMED CORPORATION | Liquid | ESTRADIOL VALERATE 10 MG | Cancelled Post Market |
| 00545996 | NEO-DIOL INJ 20MG/ML | NEOLAB INC | Liquid | ESTRADIOL VALERATE 20 MG | Cancelled Post Market |
| 00741930 | PMS-ESTRADIOL VALERATE INJ 10MG/ML | PHARMASCIENCE INC | Liquid | ESTRADIOL VALERATE 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 12976 | 2012-01-30 | New Drug Submission (NDS) |
International API supply for ESTRADIOL VALERATE
2 valid EDQM Certificates of Suitability from 2 holders. 5 active FDA Drug Master Files.
Request a quote for NATAZIA